Twist Bioscience Corporation announced a research collaboration with Astellas Pharma Inc. to discover antibodies against multiple targets of interest to develop curative therapies for patients suffering from diseases that lack treatment options. Under the terms of the agreement, Twist will conduct antibody discovery activities against multiple targets identified by Astellas. In addition to an upfront payment and project specific research fees, Twist will be eligible to receive up to USD 11 million per product through payments associated with specific clinical and commercial milestones.

Twist will also be eligible to receive royalty payments on product sales. Astellas will be responsible for the development, manufacturing and commercialization of any such products.